Vaccinia Virus Strain New York City Board Of Health Live Antigen

For adults (18 years and older), the dosage of Vaccinia Virus Strain NYCBOH is standardized by the administration technique rather than a volume-based measurement.

• Primary Vaccination (First-timers): The healthcare provider uses a bifurcated needle dipped into the vaccine solution. The needle is then used to perform 15 rapid perpendicular pricks (strokes) into the superficial skin of the upper arm (deltoid area). The pricks should be vigorous enough to cause a trace of blood to appear within 15 to 20 seconds.
• Revaccination: For individuals who have been vaccinated previously, the same technique is used, but the number of pricks may be adjusted based on the time since the last dose, though 15 pricks is the standard modern protocol to ensure a 'take.'

Vaccinia Virus Strain NYCBOH is generally not recommended for pediatric populations in non-emergency settings. In the event of a smallpox emergency, health authorities may issue specific guidance for children. There is no standard routine pediatric dose because the risk of severe complications, such as post-vaccinial encephalitis, is statistically higher in infants than in adults. If administration is deemed necessary by a physician in an emergency, the technique remains similar to adult administration, but with extreme caution regarding site care to prevent accidental spread.

Renal Impairment

No dosage adjustments are required for patients with renal impairment, as the vaccine is not cleared through the kidneys. However, the overall health and immune status of the patient must be evaluated.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment. The live virus replication is localized to the skin and does not involve hepatic metabolism.

Elderly Patients

Clinical trials for the NYCBOH strain (specifically ACAM2000) did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. Healthcare providers typically assess the cardiovascular health of elderly patients closely before administration due to the risk of myopericarditis.

This vaccine must be administered by a trained healthcare professional using the multiple-puncture technique.

• Site Preparation: The skin is usually cleaned with soap and water if needed, but alcohol should be avoided or allowed to dry completely, as it can inactivate the live virus.
• Aftercare: The site must be covered with a porous bandage (like gauze) and a semi-permeable dressing to prevent the virus from spreading.
• Clothing: Long sleeves should be worn to provide an extra layer of protection.
• Disposal: Any bandages or scabs that fall off must be placed in a plastic zip-top bag and disposed of as biohazardous waste or treated with bleach.
• Storage: Before reconstitution, the vaccine is stored in a refrigerator (2°C to 8°C). Once reconstituted, it has a limited shelf life (typically 30 days if refrigerated).

As this is typically a single-dose primary vaccination or a booster given every 3-10 years for high-risk individuals, 'missing a dose' usually refers to a failed 'take.' If a Jennerian vesicle does not develop within 6 to 11 days, the vaccination is considered unsuccessful, and the healthcare provider will typically repeat the procedure.

An overdose in the traditional sense is unlikely due to the puncture method. However, 'over-administration' (too many punctures or too much volume) could potentially increase the severity of the local reaction. The primary concern with excessive viral load is the increased risk of systemic spread or severe local necrosis. In cases of accidental ingestion or massive exposure, contact a poison control center and an infectious disease specialist immediately.

> Important: Follow your healthcare provider's dosing instructions and site-care protocols meticulously. Do not adjust your bandage or touch the vaccination site without medical guidance.

The majority of recipients of the Vaccinia Virus Strain NYCBOH will experience a range of 'expected' reactions that indicate the vaccine is working. These are often referred to as 'normal' side effects:

• Inoculation Site Lesion: A papule develops in 3-5 days, becoming a vesicle (blister) by day 7-8, then a pustule, and finally a scab. This is the 'take' reaction.
• Lymphadenopathy: Swelling and tenderness of the lymph nodes under the arm (axillary nodes) is very common as the immune system responds.
• Fever and Malaise: Many patients experience a low-grade fever, chills, and a general feeling of being unwell for 2-3 days following the peak of the local reaction.
• Myalgia and Headache: Muscle aches and headaches are frequently reported during the first week.
• Itching: Intense itching at the vaccination site is common but must be managed without scratching to prevent spreading the virus.

• Large Local Reactions: Some individuals develop a very large area of redness and swelling (sometimes called 'robust take') that can extend several inches from the site.
• Satellite Lesions: Small secondary blisters may form immediately adjacent to the primary vaccination site.
• Fatigue: Significant tiredness that may interfere with daily activities for 1-4 days.

• Generalized Vaccinia: A rash consisting of vaccinia-like lesions appearing on various parts of the body. In healthy individuals, this is usually self-limiting.
• Erythema Multiforme: A skin reaction that can look like 'targets' or 'bullseyes' on the skin, thought to be an immune-mediated response.
• Inadvertent Inoculation: Transferring the virus from the vaccination site to other areas (like the eyes, mouth, or genitals) by touching the site and then touching another part of the body.

> Warning: Stop activities and call your doctor immediately if you experience any of these symptoms. These conditions can be life-threatening.

• Myocarditis and Pericarditis: Inflammation of the heart muscle or the sac around the heart. Symptoms include chest pain, shortness of breath, or a racing heartbeat. This occurs in approximately 1 in 175 primary vaccinees.
• Post-vaccinial Encephalitis (PVE): Inflammation of the brain, which can cause permanent neurological damage or death. Symptoms include high fever, seizure, confusion, or coma.
• Progressive Vaccinia (Vaccinia Necrosum): A life-threatening condition where the vaccination site does not heal but instead continues to expand and kill surrounding tissue. This occurs almost exclusively in people with weakened immune systems.
• Eczema Vaccinatum: A severe, widespread skin infection occurring in people with a history of eczema or atopic dermatitis. It can lead to systemic illness and death.
• Ocular Vaccinia: Infection of the eye, which can lead to corneal scarring and permanent vision loss.

Most side effects of the NYCBOH strain are acute and resolve within a month. However, serious complications like myocarditis can sometimes lead to long-term heart function issues, though most cases appear to resolve with treatment. Scarring at the vaccination site is permanent and is a hallmark of having received the smallpox vaccine.

The FDA has issued a Black Box Warning for vaccines containing Vaccinia Virus Strain NYCBOH (such as ACAM2000). The warning highlights:

1. 1Myocarditis and Pericarditis: The risk of heart inflammation is significant and can occur in otherwise healthy individuals.
2. 2Spread of Virus: The live virus can be transmitted to close contacts, who may then suffer the same serious side effects (like eczema vaccinatum) even if they were not vaccinated themselves.
3. 3Fetal Risk: Vaccination during pregnancy can lead to fetal vaccinia, a rare but often fatal infection of the fetus.

Report any unusual symptoms, especially chest pain or vision changes, to your healthcare provider immediately.

Vaccinia Virus Strain NYCBOH is a live, infectious virus. Unlike most vaccines, the recipient is 'contagious' at the site of injection until the scab falls off. Strict adherence to hand hygiene and site covering is mandatory to prevent spreading the virus to other parts of the body or to other people.

WARNING: CARDIAC COMPLICATIONS, FETAL DEATH, AND TRANSMISSION

• Myocarditis and Pericarditis: Data from clinical trials indicated a risk of approximately 5.7 per 1000 primary vaccinees. Patients must be monitored for chest pain, dyspnea, or other cardiac symptoms.
• Transmission: The virus can be transmitted to household contacts. High-risk contacts (those with eczema, pregnancy, or immunodeficiency) are at risk for severe complications if they accidentally touch the vaccine site or contaminated materials.
• Fetal Vaccinia: Live vaccinia virus can cause fetal infection, leading to stillbirth or neonatal death. Pregnancy must be avoided for 4 weeks post-vaccination.

• Allergic Reactions: Anaphylaxis is rare but possible. The vaccine contains trace amounts of antibiotics (neomycin and polymyxin B) and glycerin. Individuals with known allergies to these components should not receive the vaccine.
• Atopic Dermatitis/Eczema: Even a history of these conditions, even if not currently active, increases the risk of life-threatening eczema vaccinatum.
• Immunosuppression: Those with HIV/AIDS, cancer, or those taking immunosuppressive drugs (steroids, chemotherapy) are at extreme risk for progressive vaccinia.
• Eye Protection: If the virus enters the eye, it can cause blindness. Avoid touching the site and then rubbing the eyes.

Patients should be monitored by their healthcare provider at the following intervals:

• Day 7-10: To check for a 'take' (successful immune response).
• Cardiac Monitoring: Patients should be advised to self-monitor for heart symptoms for at least 30 days.
• Lab Tests: In cases of suspected myocarditis, EKG and troponin levels are required.

There are no specific restrictions on driving, provided the patient does not have a high fever or severe malaise that impairs concentration. However, if systemic symptoms like dizziness or severe headache occur, patients should avoid these activities.

While there is no direct chemical interaction between alcohol and the vaccinia virus, alcohol can suppress the immune system and may worsen the systemic side effects (fever, headache). It is generally advised to avoid excessive alcohol during the peak of the immune response (7-14 days post-vaccination).

Once the vaccine is administered, it cannot be 'discontinued' as it is a one-time live viral inoculation. If severe adverse reactions occur, specialized treatments like Vaccinia Immune Globulin (VIG) or antiviral drugs like tecovirimat (TPOXX) may be administered by specialists.

> Important: Discuss all your medical conditions, especially skin conditions and heart history, with your healthcare provider before starting Vaccinia Virus Strain New York City Board Of Health Live Antigen.

• Immunosuppressive Therapy: High-dose corticosteroids (e.g., prednisone >20mg/day), alkylating agents, antimetabolites, and radiation therapy. These drugs prevent the immune system from controlling the live virus, which can lead to Progressive Vaccinia (a fatal spreading of the virus).
• TNF Inhibitors and Biologics: Drugs like adalimumab or etanercept significantly increase the risk of systemic viral spread.

• Other Live Vaccines: Generally, other live vaccines (like MMR or Varicella) should be given either on the same day or separated by at least 4 weeks. Administering them too close together may interfere with the immune response to one or both vaccines.
• Topical Steroids: Applying steroid creams near the vaccination site can suppress the local immune response and allow the virus to spread uncontrollably in the skin.

• Antiviral Agents: Drugs like cidofovir or tecovirimat are active against vaccinia virus. If taken concurrently with the vaccine, they may 'kill' the vaccine virus before it can induce immunity, leading to a failed vaccination.
• Salicylates (Aspirin): In children, the use of aspirin during a viral infection or live-virus vaccination is associated with Reye’s Syndrome. While the vaccine is rarely given to children, this remains a theoretical risk.

There are no known specific food interactions with Vaccinia Virus Strain NYCBOH. However, maintaining adequate hydration is important during the period of fever and malaise.

• Echinacea and Immune Stimulants: While often used to 'boost' the immune system, there is no evidence they help the vaccine work better, and they could theoretically alter the inflammatory response at the site.
• St. John’s Wort: No direct interaction, but as it affects the metabolism of many other drugs, patients should inform their doctor if they are using it.

• Tuberculin Skin Test (PPD): Live viral vaccines can cause a temporary loss of tuberculin skin sensitivity, leading to a false-negative result. PPD tests should be done either on the same day as vaccination or delayed for 4-6 weeks.
• Troponin Levels: The vaccine may cause transient elevations in cardiac troponin if subclinical myocarditis occurs.

For each major interaction, the mechanism is usually related to either pharmacodynamic interference (suppressing the immune response needed for the vaccine to work) or increased toxicity (allowing the live virus to replicate without check).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter creams and ointments.

Vaccinia Virus Strain NYCBOH must NEVER be used in the following individuals in a non-emergency setting:

• Immunodeficiency Disorders: This includes patients with HIV/AIDS, severe combined immunodeficiency (SCID), or those undergoing bone marrow transplants. The mechanism is the inability of the body to stop the replication of the live vaccinia virus.
• History of Eczema or Atopic Dermatitis: Even if the condition is currently inactive or occurred only in childhood. The skin barrier defect in these patients allows the virus to spread rapidly across the skin (Eczema Vaccinatum).
• Pregnancy: The virus can cross the placenta and cause fetal death.
• Infants under 12 months: High risk of neurological complications.
• Known Allergy to Vaccine Components: Specifically neomycin, polymyxin B, or glycerin.

• Household Contacts with Contraindications: If you live with someone who is pregnant, has eczema, or is immunocompromised, you should generally not receive the vaccine because you can pass the virus to them through casual contact.
• Active Skin Conditions: Conditions like psoriasis, severe acne, or shingles at the site of vaccination should be allowed to heal before administration.
• Cardiac Risk Factors: People with three or more risk factors for heart disease (smoking, high blood pressure, diabetes, etc.) should use caution due to the risk of myocarditis.

Individuals who have had severe reactions to previous orthopoxvirus vaccines (like the older Dryvax) are likely to react similarly to the NYCBOH strain in ACAM2000. There is also potential cross-sensitivity for those allergic to aminoglycoside antibiotics.

> Important: Your healthcare provider will evaluate your complete medical history and your household environment before prescribing Vaccinia Virus Strain New York City Board Of Health Live Antigen.

Vaccinia Virus Strain NYCBOH is contraindicated during pregnancy. It is classified as a high-risk agent for fetal vaccinia, which involves the fetus developing vaccinia lesions similar to the vaccination site. This often results in preterm delivery, stillbirth, or neonatal death. Women of childbearing age should have a pregnancy test before vaccination and must use effective contraception to avoid pregnancy for at least 4 weeks after receiving the vaccine.

It is not known if the vaccinia virus is excreted in human milk. However, the primary risk is not through the milk itself, but through the physical contact between the infant and the vaccination site or contaminated clothing. Because infants are at high risk for complications, breastfeeding is generally discouraged unless the mother can ensure no contact between the baby and the vaccination site.

In routine settings, this vaccine is not approved for use in children under 18. Historically, pediatric use was associated with higher rates of post-vaccinial encephalitis (PVE). In a smallpox emergency, the benefits may outweigh the risks, but this would be managed under strict public health protocols.

Elderly patients may have a diminished immune response to the vaccine. Furthermore, the increased prevalence of cardiovascular disease in this population makes the risk of vaccine-induced myocarditis a more significant concern. Clinical monitoring of heart function is essential for older adults.

Renal impairment does not affect the clearance of the live virus. However, patients with end-stage renal disease (ESRD) are often considered functionally immunocompromised, which may increase the risk of complications. Dose adjustments are not needed, but clinical vigilance is required.

Hepatic impairment does not alter the pharmacology of the NYCBOH strain. However, patients with severe liver disease may have altered immune profiles. No specific dose adjustment is recommended, but the patient's overall stability should be assessed.

> Important: Special populations require individualized medical assessment and often a formal 'screening' process to ensure safety.

Vaccinia Virus Strain NYCBOH is a live-virus vaccine. Its molecular mechanism involves the infection of host keratinocytes at the site of inoculation. The virus enters the cell, releases its DNA into the cytoplasm, and hijacks the host's cellular machinery to replicate. This localized infection releases viral proteins that are processed by antigen-presenting cells (APCs). These APCs travel to local lymph nodes and present the vaccinia antigens to T-cells and B-cells. This results in the production of memory B-cells (which produce antibodies) and cytotoxic T-cells (which kill virus-infected cells). Because vaccinia and variola (smallpox) share many surface antigens, the immune system becomes 'primed' to recognize and destroy the smallpox virus if it ever enters the body.

• Onset of Immunity: Neutralizing antibodies typically appear within 10-14 days after a successful primary vaccination.
• Duration of Effect: High-level protection lasts 3-5 years. Immunological memory can persist for decades, but booster doses are recommended every 10 years for those with ongoing high-risk exposure.
• Tolerance: There is no 'tolerance' in the pharmacological sense, but revaccination usually results in a milder local reaction (accelerated reaction) because existing immunity partially limits the new viral replication.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local replication) |

| Protein Binding | N/A |

| Duration of Shedding | 14-21 days (until scab falls) |

| Tmax (Viral Load at Site) | 7-10 days |

| Metabolism | Host cellular degradation |

| Excretion | Scab desquamation |

The vaccine consists of live Vaccinia virus, a large, enveloped, double-stranded DNA virus. The NYCBOH strain is characterized by its specific genomic sequence, which is less virulent than other historical strains like the Western Reserve strain. It is suspended in a clear to slightly milky solution after reconstitution.

Vaccinia Virus Strain NYCBOH is classified as a Live Viral Vaccine. It is specifically an Orthopoxvirus vaccine. It is related to other vaccines like JYNNEOS, but JYNNEOS uses a non-replicating strain (MVA), whereas the NYCBOH strain in ACAM2000 is fully replicating.